Ami Fadia
Stock Analyst at Needham
(4.53)
# 294
Out of 5,182 analysts
356
Total ratings
50.16%
Success rate
29.05%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $145 → $186 | $133.42 | +39.41% | 29 | Apr 20, 2026 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $510 | $325.00 | +56.92% | 18 | Apr 14, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $37 | $28.38 | +30.37% | 1 | Apr 8, 2026 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $185 | $129.12 | +43.28% | 18 | Apr 6, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Hold | n/a | $39.37 | - | 2 | Mar 31, 2026 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $8 | $2.17 | +268.66% | 11 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $24 → $15 | $4.83 | +210.56% | 22 | Mar 18, 2026 | |
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $4.56 | +207.02% | 2 | Mar 9, 2026 | |
| IMRX Immuneering | Reiterates: Buy | $11 | $5.90 | +86.60% | 21 | Mar 9, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Hold | n/a | $21.53 | - | 24 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $32 | $18.79 | +70.30% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $44 | $31.98 | +37.59% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $225 | $180.90 | +24.38% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $235 | $199.20 | +17.97% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $35.85 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $21.67 | +33.83% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $33.37 | +31.85% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $184.32 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $14.85 | +2,054.88% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $25.37 | +195.62% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $11.73 | +437.08% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $30.99 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $0.98 | +2,135.09% | 4 | Jan 3, 2018 |
Revolution Medicines
Apr 20, 2026
Maintains: Buy
Price Target: $145 → $186
Current: $133.42
Upside: +39.41%
Praxis Precision Medicines
Apr 14, 2026
Reiterates: Buy
Price Target: $510
Current: $325.00
Upside: +56.92%
MapLight Therapeutics
Apr 8, 2026
Initiates: Buy
Price Target: $37
Current: $28.38
Upside: +30.37%
Neurocrine Biosciences
Apr 6, 2026
Reiterates: Buy
Price Target: $185
Current: $129.12
Upside: +43.28%
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $39.37
Upside: -
Neumora Therapeutics
Mar 31, 2026
Reiterates: Buy
Price Target: $8
Current: $2.17
Upside: +268.66%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $24 → $15
Current: $4.83
Upside: +210.56%
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $4.56
Upside: +207.02%
Immuneering
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.90
Upside: +86.60%
Day One Biopharmaceuticals
Mar 6, 2026
Downgrades: Hold
Price Target: n/a
Current: $21.53
Upside: -
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $18.79
Upside: +70.30%
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $31.98
Upside: +37.59%
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $180.90
Upside: +24.38%
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $199.20
Upside: +17.97%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $35.85
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $21.67
Upside: +33.83%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $33.37
Upside: +31.85%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $184.32
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $14.85
Upside: +2,054.88%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $25.37
Upside: +195.62%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $11.73
Upside: +437.08%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $30.99
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $0.98
Upside: +2,135.09%